S&P 500 Futures
(-0.12%) 5 302.00 points
Dow J Futures
(-0.02%) 40 134 points
Nasdaq Futures
(-0.20%) 18 468 points
Oil
(0.45%) $81.72
Gas
(-1.51%) $1.692
Gold
(0.16%) $2 216.30
Silver
(-0.83%) $24.55
Platinum
(-0.26%) $907.30
USD/EUR
(0.44%) $0.928
USD/NOK
(0.72%) $10.85
USD/GBP
(0.37%) $0.794
USD/RUB
(-0.10%) $92.35

Realtime updates for Spectrum Pharmaceuticals [SPPI]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Last Updated31 Jul 2023 @ 15:56

-0.49% $ 1.025

Live Chart Being Loaded With Signals

Commentary (31 Jul 2023 @ 15:56):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Spectrum Pharmaceuticals Inc

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma...

Stats
Today's Volume 4.85M
Average Volume 1.64M
Market Cap 210.38M
EPS $0 ( 2024-03-20 )
Next earnings date ( $0 ) 2024-05-07
Last Dividend $0.150 ( 2012-12-18 )
Next Dividend $0 ( N/A )
P/E -2.85
ATR14 $0.0510 (4.95%)
Insider Trading
Date Person Action Amount type
2023-07-31 Bradrick Brittany Sell 27 380 Common Stock, $0.001 par value
2023-07-31 Bradrick Brittany Sell 86 301 Stock Option (Right to Buy)
2023-07-31 Mcgahan Keith M Sell 195 485 Common Stock, $0.001 par value
2023-07-31 Mcgahan Keith M Sell 386 057 Common Stock, $0.001 par value
2023-07-31 Mcgahan Keith M Sell 778 000 Stock Option (Right to Buy)
INSIDER POWER
-22.47
Last 97 transactions
Buy: 24 888 642 | Sell: 15 180 768

Volume Correlation

Long: 0.14 (neutral)
Short: 0.79 (moderate)
Signal:(56.794) Neutral

Spectrum Pharmaceuticals Correlation

10 Most Positive Correlations
IRMD0.941
IDCC0.939
SLMBP0.939
DRNA0.933
PRAA0.924
MESA0.923
PIRS0.923
GALT0.922
HLIO0.92
IOAC0.919
10 Most Negative Correlations
GMII-0.923
AVIR-0.911
TUEM-0.907
JRJC-0.896
AFYA-0.896
EAR-0.887
GSMG-0.885
DTSS-0.883
ATSG-0.881
GOEV-0.88

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Spectrum Pharmaceuticals Correlation - Currency/Commodity

The country flag 0.32
( neutral )
The country flag -0.10
( neutral )
The country flag 0.00
( neutral )
The country flag 0.16
( neutral )
The country flag 0.57
( weak )
The country flag -0.25
( neutral )

Spectrum Pharmaceuticals Financials

Annual 2022
Revenue: $10.11M
Gross Profit: $8.32M (82.28 %)
EPS: $-0.430
Q1 2023
Revenue: $15.62M
Gross Profit: $14.55M (93.19 %)
EPS: $-0.0255
Q4 2022
Revenue: $10.11M
Gross Profit: $8.32M (82.28 %)
EPS: $-0.0488
Q3 2022
Revenue: $0
Gross Profit: $-3 000.00 (0.00 %)
EPS: $-0.120

Financial Reports:

No articles found.

Spectrum Pharmaceuticals Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Spectrum Pharmaceuticals Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $0.150 2012-12-18
Last Dividend $0.150 2012-12-18
Next Dividend $0 N/A
Payout Date 2012-12-28
Next Payout Date N/A
# dividends 1 --
Total Paid Out $0.150 --
Avg. Dividend % Per Year 0.00% --
Score 0.01 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-03-28)
$0 Estimate 0.00 %
Dividend Stability
0.00 Very Bad
Dividend Score
0.01
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield
2012 $0.150 1.02%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-1.4001.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.3341.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-1.1931.500-10.00-10.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM2.710.8001.4491.159[1 - 3]
quickRatioTTM2.310.8001.1240.899[0.8 - 2.5]
cashRatioTTM1.3471.5003.635.44[0.2 - 2]
debtRatioTTM0.275-1.5005.42-8.12[0 - 0.6]
interestCoverageTTM-19.331.000-8.27-8.27[3 - 30]
operatingCashFlowPerShareTTM-0.3202.00-0.107-0.214[0 - 30]
freeCashFlowPerShareTTM-0.3222.00-0.161-0.322[0 - 20]
debtEquityRatioTTM1.105-1.5005.58-8.37[0 - 2.5]
grossProfitMarginTTM0.8891.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-1.4811.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-2.181.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.2390.800-1.740-1.392[0.5 - 2]
Total Score-3.02

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-5.751.000-0.6820[1 - 100]
returnOnEquityTTM-1.1932.50-9.24-10.00[0.1 - 1.5]
freeCashFlowPerShareTTM-0.3222.00-0.107-0.322[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.3202.00-0.107-0.214[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.5831.5009.450[0.5 - 2]
operatingCashFlowSalesRatioTTM-2.511.000-10.000[0.1 - 0.5]
Total Score-1.111

Spectrum Pharmaceuticals

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators